

## SARC Biannual Meeting Agenda

October 27, 2011

8:00 am - 12:00 pm

<b>8:00</b>	<b>Introduction</b>	
	CTOS Welcome	Lor Randall
	SARC Developmental Therapeutics Committee Update	Chand Khanna
	Clinical and biologic heterogeneity in Ewing sarcoma: Challenges for therapy	Beth Lawlor
<b>9:15</b>	<b>SARC Career Development</b>	
	Career Development Update	Lee Helman
	Identification of small molecule inhibitors of the EWS-FLI1 transcriptional program to treat Ewing sarcoma	Patrick Grohar
<b>9:45</b>	<b>Break</b>	
<b>10:00</b>	<b>SARC Clinical Trials</b>	
	SARC Clinical Research Committee Update	Shreyaskumar Patel
	Clinical Trials Update	Rashmi Chugh
	<b>SARC021</b> Randomized phase 3 trial of TH-302+doxorubicin versus doxorubicin in advanced/metastatic soft tissue sarcoma	Rashmi Chugh on behalf of Bill Tap
	<b>SARC005</b> Adjuvant chemotherapy in uterine leiomyosarcoma: What have we learned and future directions	Martee Hensley
	<b>SARC006</b> Malignant peripheral nerve sheath tumors: Understanding the role of chemotherapy in sporadic versus NF-1 associated tumors	Brigitte Widemann
	<b>SARC012</b> Resected recurrent osteosarcoma	Lee Helman
	<b>SARC022</b> Wild-type and pediatric GIST and anti-IGF-1R therapy	Meg von Mehren
	<b>SARC020/EORTC</b> Trabectedin versus doxorubicin for first-line therapy of metastatic soft tissue sarcoma	James Butrynski
<b>11:40</b>	<b>Closing Remarks</b>	
		McHenry Tichenor